DURHAM, N.C., Nov. 12, 2025 (GLOBE NEWSWIRE) — Velocity Clinical Research (Velocity), the leading fully integrated site organization, today announces the appointment of Andrew (Drew) Reina as Chief Revenue Officer (CRO), effective immediately. Drew joins from Fortrea, one of the world's leading contract research organizations (CROs), where he held senior leadership roles driving growth strategies […]

A refreshing passionfruit energy boost with zero sugar and full Monster attitude. Monster Energy is bringing the heat with the newest addition to its fan-favorite Monster Energy Ultra lineup: Ultra Wild Passion, a bold, vibrant and refreshingly light passionfruit flavor that delivers energy with zero sugar and all the attitude. https://mma.prnewswire.com/media/2820661/Monster_Ultra_Wild_Passion.jpg Ultra Wild Passion pairs

Velocity Clinical Research Appoints Former Fortrea Executive, Andrew Reina, as Chief Revenue Officer Firm to target small to medium-sized biotech and pharma companies GlobeNewswire November 12, 2025 DURHAM, N.C., Nov. 12, 2025 (GLOBE NEWSWIRE) — Velocity Clinical Research (Velocity), the leading fully integrated site organization, today announces the appointment of Andrew (Drew) Reina as Chief

(NASDAQ:UNCY), – Remain on track to resubmit the New Drug Application (NDA) for oxylanthanum carbonate (OLC) by year end – Presented new analysis of OLC data at American Society of Nephrology (ASN) which demonstrates that OLC significantly reduced pill burden in terms of both pill volume (7x) and pill count (2x) compared to currently available

(NASDAQ:ZBIO), – Obexelimab Phase 3 INDIGO trial topline results in Immunoglobulin G4-Related Disease (IgG4-RD) expected around year-end 2025 – – Reported highly positive 12-week primary endpoint results from Phase 2 MoonStone trial of obexelimab in Relapsing MS (RMS) – – Secured development and commercialization rights for three autoimmune product candidates, including orelabrutinib, a BTK Inhibitor

Quick service restaurants with the strongest customer value propositions grew six times faster than most competitors dunnhumby, a global leader in customer data science, has named Buc-ee's as the top ranked U.S. quick service restaurant (QSR) in the Retailer Preference Index (RPI) QSR Edition. The RPI is a nationwide brand equity study that examines the

Brings Science-Backed, Transparency Driven Barrier Repair Worldwide Epicutis®, the science-driven skincare brand by biotech innovator Signum Biosciences, proudly announces its continued international expansion with the establishment of new offices in Sydney, Australia and Kyoto, Japan. This milestone marks a major step forward in Epicutis' mission to make clinical-grade, EWG-Verified skincare accessible to professionals and consumers

Achieves year-over-year gross margin expansion and $13.7 million increase in operating income – Updates full-year sales and adjusted EBITDA guidance – Pyxus International, Inc. (OTCID: PYYX) (“Pyxus,” the “Company,” “we,” or “our”), a global value-added agricultural company, today announced results for its second quarter ended September30, 2025. https://mma.prnewswire.com/media/1705892/Pyxus_Logo.jpg Pieter Sikkel, Pyxus' President and Chief Executive

Unicycive Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update GlobeNewswire November 12, 2025 – Remain on track to resubmit the New Drug Application (NDA) for oxylanthanum carbonate (OLC) by year end – Presented new analysis of OLC data at American Society of Nephrology (ASN) which demonstrates that OLC significantly reduced pill burden

Zenas BioPharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update GlobeNewswire November 12, 2025 – Obexelimab Phase 3 INDIGO trial topline results in Immunoglobulin G4-Related Disease (IgG4-RD) expected around year-end 2025 – – Reported highly positive 12-week primary endpoint results from Phase 2 MoonStone trial of obexelimab in Relapsing MS (RMS) – –